Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States.Jorge J. Castillo, Boxiong Tang, Aileen Cohen et al.|Journal of Clinical Oncology|2021Cited by 6
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): Matching-adjusted indirect comparisons.Jorge J. Castillo, Boxiong Tang, Keri Yang et al.|Journal of Clinical Oncology|2021Cited by 2